Research progress on the application of nafamostat anticoagulation in continuous renal replacement therapy
Zhou Xinrui
Shen Qing
Abstract：Continuous renal replacement therapy(CRRT)is a widely used blood purification technique in extracorporeal circulation,and coagulation in the extracorporeal circulation circuit is one of its common complications.Heparin is commonly used as a circulating anticoagulant in clinical practice,but the higher risk of bleeding makes this regimen not suitable for patients with abnormal coagulation function.Nafamostat has a strong anticoagulant effect and a low risk of bleeding,which is more suitable for patients with high bleeding risk.This article reviews the clinical research progress of nafamostat in CRRT,in order to provide some reference value for the selection of anticoagulants for CRRT.
Keywords：Continuous renal replacement therapyNafamostatAnticoagulant
Publication Date：2024-08-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 1263-1266 )